Nicole Jadeja
I am an IP litigator specialising in patent litigation in the life sciences sector. Having graduated with a science degree, I spent several years working in clinical trials in the pharmaceutical industry, before qualifying as a lawyer. Whilst I have litigated all types of IP, my experience in recent years has been litigating for pharmaceutical companies.
As well as being an experienced litigator in the UK Courts and the European Patent Office, I have experience of litigating in the Court of Justice of the European Union having worked on two seminal cases which were referred to this Court, one concerning SPCs and one concerning counterfeit goods in transit. I frequently advise on multi-jurisdiction patent disputes, co-coordinating litigation in various European and other jurisdictions.
I am Vice Chair of the IP Committee of the BioIndustry Association and a member of the Life Sciences Committee of the Chartered Institute of Patent Attorneys. I frequently speak at industry events, particularly on SPCs.
Practice Area
Panel
- Contributing Author
Qualified Year
- 2005
Membership
- Chartered Institute of Patent Attorneys
- Bio Industry Association
Education
- Loughborough University - Bsc (Hons) Human Biology 1st
- University of Bristol - Diploma in Intellectual Property Law
- College of Law, London - PGDL and LPC Law
3 Contributions by Nicole Jadeja
PRACTICE NOTES
Biotechnology patentability in the UK and EU: Directive 98/44/EC, EPC Article 53(b), PA 1977 Sch A2, key CJEU/EPO case law, exclusions, and compulsory cross-licences
This Practice Note outlines which biotechnological inventions may and may not be patented. It cites Directive 98/44/EC (commonly called the Biotechnology Directive) and Schedule A2 to the Patents Act 1977 (PA 1977), which allow patents for biotechnological inventions while setting key exceptions. Those exceptions have been interpreted by the Court of Justice in cases including Oliver Brüstle v Greenpeace and Monsanto v Cefetra. The Note also reviews exclusions from patentability under Article 52(b) of the European Patent Convention (EPC) and pertinent European Patent Office (EPO) decisions, Tomatoes I, Tomatoes II and Broccoli II. It also takes account of the 2017 European Commission Notice on biotechnological inventions.
Patenting biotechnological inventions
As a general rule, biotechnological inventions are patentable. Although neither PA 1977 nor the EPC imposes a blanket prohibition, specific provisions control when such inventions can be protected (see: The regulatory framework for biotechnology patents below). Additionally, in practice, some biotechnological subject-matter, even if not expressly barred, may fail the standard thresholds of novelty, inventive step and industrial applicability. For further detail on these criteria, see Practice Note: Patentability and exclusions from patentability...
Life Sciences
PRACTICE NOTES
EU supplementary protection certificates and paediatric extensions: eligibility, duration, applications, manufacturing waiver, CJEU case law, and reforms including unitary SPCs, biotech SPC extension and crisis compulsory licensing
This Practice Note introduces supplementary protection certificates (SPCs) and paediatric extensions (PEs) in the EU. It sets out why they were created, when and how to seek them, and their duration. It also reviews leading Court of Justice rulings interpreting Regulation (EC) 469/2009 and Regulation (EC) 1610/96, the regimes governing SPCs for medicinal products and plant protection products (PPPs) in the EU...
Supplementary protection certificates (SPCs)
What is an SPC?
An SPC continues the protection afforded by a patent for a specific medicinal or plant protection product for up to five years, subject to meeting defined criteria (see: Conditions for obtaining an SPC in an EU Member State below). It does not prolong the patent term for subject-matter beyond the SPC’s scope and is therefore not a ‘patent term extension’ in itself. The rights conferred by an SPC in relation to the product mirror those granted by the underlying patent. For further detail on patents, see Practice Note: Introduction to patents. An SPC is a national right and, in the EU, operates at that level...
EU Law
PRACTICE NOTES
UK SPCs and paediatric extensions for medicinal and plant protection products: regime, applications, duration, manufacturing waiver, and leading CJEU/UK case law post‑Brexit and under the Windsor Framework
This Practice Note introduces supplementary protection certificates (SPCs) and paediatric extensions (PEs) in the UK. It outlines the reasons for their creation, when and how to apply, and how long they run. It also reviews leading rulings on SPCs from the courts of England and Wales, together with UK Intellectual Property Office (IPO) guidance on SPC procedure...
It further surveys numerous references to the Court of Justice on the interpretation of Regulation (EC) 469/2009 and Regulation (EC) 1610/96, which regulate SPCs for medicinal products and plant protection products within the EU (and, before Brexit, in the UK). The resulting Court of Justice decisions have defined the scope of SPC protection across the EU and the UK. For guidance on whether Court of Justice rulings bind UK courts, see Practice Note: Assimilated law—Assimilated case law. For a discussion confined to the EU SPC regime, see Practice Note: Supplementary protection certificates and paediatric extensions—EU...
Supplementary protection certificates (SPCs)
What is an SPC?
An SPC prolongs the protection provided by a patent for a specific plant protection or medicinal product by up to five years, subject to certain conditions...
Life Sciences
If you expected to see yourself on this page, click here.
